BR112012014558A2 - nova composição dexibuprofeno hidrogel transdérmica - Google Patents

nova composição dexibuprofeno hidrogel transdérmica

Info

Publication number
BR112012014558A2
BR112012014558A2 BR112012014558A BR112012014558A BR112012014558A2 BR 112012014558 A2 BR112012014558 A2 BR 112012014558A2 BR 112012014558 A BR112012014558 A BR 112012014558A BR 112012014558 A BR112012014558 A BR 112012014558A BR 112012014558 A2 BR112012014558 A2 BR 112012014558A2
Authority
BR
Brazil
Prior art keywords
dexibuprofen
hydrogel
transdermal
prepared
composition
Prior art date
Application number
BR112012014558A
Other languages
English (en)
Other versions
BR112012014558B1 (pt
BR112012014558A8 (pt
BR112012014558B8 (pt
Inventor
Vel Palansisamy Anadsensenthil
Stuart Bergman Jeffrey
Devarajan Sampathkumar
Ramalingam Selvakumar
Original Assignee
Shasun Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shasun Pharmaceuticals Ltd filed Critical Shasun Pharmaceuticals Ltd
Publication of BR112012014558A2 publication Critical patent/BR112012014558A2/pt
Publication of BR112012014558A8 publication Critical patent/BR112012014558A8/pt
Publication of BR112012014558B1 publication Critical patent/BR112012014558B1/pt
Publication of BR112012014558B8 publication Critical patent/BR112012014558B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

nova composição dexibuprofeno hidrogel transdérmica a presente invenção refere-se a um hidrogel não alcóolica estável transdérmica de dexibuprofeno foi preparado usando um processo de fabrico simples, e os ensaios experimentais mostraram que o ph modificando antioxidante agente, e solvente miscível com água são os excipientes essenciais para a obtenção de hidrogel não alcóolica estável transdérmica de dexibuprofeno. o hidrogel dexibuprofeno preparados utilizando carbopol como uma gelificação do polímero produzindo um gel opaco, enquanto que hidrogel preparados utilizando hyroxupropyl metilcelulose (hpmc) como um gelificante polímero produzido um gel transparente. não houve alterações siginificativas observadas com respeito à descrição física, ph ensaio, e particularmente para os valores de subsutâncias afins, quando os hidrogéis foram submetidos ao estudo de estabilidade a condição acelerada (40<198>c hr/75%) durante 3 meses em tubos laminados.
BR112012014558A 2009-12-16 2010-12-09 nova composição de hidrogel transdérmico de dexibuprofeno BR112012014558B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3121CH2009 2009-12-16
IN3121/CHE/2009 2009-12-16
PCT/IN2010/000795 WO2011073998A1 (en) 2009-12-16 2010-12-09 Composition of dexibuprofen transdermal hydrogel

Publications (4)

Publication Number Publication Date
BR112012014558A2 true BR112012014558A2 (pt) 2017-12-19
BR112012014558A8 BR112012014558A8 (pt) 2018-04-10
BR112012014558B1 BR112012014558B1 (pt) 2021-02-02
BR112012014558B8 BR112012014558B8 (pt) 2021-05-25

Family

ID=54200209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014558A BR112012014558B8 (pt) 2009-12-16 2010-12-09 nova composição de hidrogel transdérmico de dexibuprofeno

Country Status (15)

Country Link
US (2) US20120259018A1 (pt)
EP (1) EP2512446B1 (pt)
JP (1) JP2013514347A (pt)
KR (1) KR101884951B1 (pt)
CN (1) CN102665681A (pt)
AU (1) AU2010331761B2 (pt)
BR (1) BR112012014558B8 (pt)
CA (1) CA2784827C (pt)
DK (1) DK2512446T3 (pt)
ES (1) ES2541483T3 (pt)
MX (1) MX352187B (pt)
PE (1) PE20130245A1 (pt)
PL (1) PL2512446T3 (pt)
RU (1) RU2012129527A (pt)
WO (1) WO2011073998A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101894891B1 (ko) * 2012-11-30 2018-09-04 동아에스티주식회사 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형
US10583036B2 (en) * 2013-01-17 2020-03-10 Kanae Technos Co., Ltd. Topical adhesive skin patch
SG11201505541VA (en) * 2013-02-14 2015-08-28 Sanofi Sa Chewable composition for oral administration and process for preparing thereof
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016007834A1 (en) 2014-07-11 2016-01-14 Novan, Inc. Topical antiviral compositions and methods of using the same
JP6865159B2 (ja) * 2014-08-20 2021-04-28 スリーエム イノベイティブ プロパティズ カンパニー 硫酸塩還元微生物用の内蔵型嫌気性培養デバイス
CN104188899A (zh) * 2014-09-26 2014-12-10 天津市聚星康华医药科技有限公司 一种洛索洛芬钠凝胶及其制备方法
CN105168117B (zh) * 2015-10-04 2018-08-07 临沂大学 一种右旋布洛芬微乳凝胶及其制备方法
JP7090549B2 (ja) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法
CN105935445B (zh) * 2016-03-28 2019-02-01 赤峰赛林泰药业有限公司 含2-(-4-异丁基苯基)丙酸右旋物的药物组合物及其制备方法
CN109310630A (zh) 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
CN106074459A (zh) * 2016-07-11 2016-11-09 雷春生 一种持久保水型水凝胶贴支持层材料的制备方法
CN112206222A (zh) * 2018-11-09 2021-01-12 北京德默高科医药技术有限公司 含有布洛芬结构类似物的多层经皮给药系统
CN111388409B (zh) * 2020-03-25 2023-01-31 牡丹江医学院 一种皮肤止痒抑菌贴剂用水凝胶材料的制备方法
EP4308088A1 (en) 2021-11-08 2024-01-24 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient
KR102419076B1 (ko) * 2022-01-17 2022-07-08 장보경 마취제 조성물 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
DE4024801A1 (de) * 1990-08-04 1992-02-06 Porsche Ag Abgasanlage einer brennkraftmaschine
HU219242B (en) * 1991-05-13 2001-03-28 Boots Co Plc S(+)-ibuprofen sodium salt dihydrate, pharmaceutical composition comprising this compound and process for production of them
CZ112496A3 (en) * 1993-10-20 1997-04-16 Boots Co Plc Application of ibuprofen and flurbiprofen as agents relieving itching and pharmaceutical preparations for such application
AT408067B (de) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
PT851908E (pt) * 1995-06-07 2003-09-30 Lee County Mosquito Control Di Composicoes e metodos lubrificantes
US20010023261A1 (en) * 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
WO1999049908A1 (en) * 1998-03-31 1999-10-07 University Of Cincinnati Temperature controlled solute delivery system
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19945522A1 (de) * 1999-09-23 2001-04-05 Hexal Ag Pharmazeutisches, wirkstoffhaltiges Gel
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
CA2445086C (en) * 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US7052715B2 (en) * 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
ES2646813T3 (es) * 2003-06-19 2017-12-18 Coloplast A/S Un dispositivo para el cuidado de heridas
KR20060037320A (ko) * 2003-07-02 2006-05-03 알자 코포레이션 미세돌출부 어레이 면역화 패치 및 방법
CH715855B1 (de) * 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
JP4128521B2 (ja) * 2003-12-19 2008-07-30 信越化学工業株式会社 ゲル状シート及びその製造方法
WO2006122183A2 (en) * 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
JP4969812B2 (ja) * 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070083147A1 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies Inc. Iontophoresis apparatus and method to deliver antibiotics to biological interfaces
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
CN101455654B (zh) * 2007-12-13 2013-03-06 天津医科大学 精氨酸布洛芬凝胶剂及其制备方法
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
CA2726726A1 (en) * 2008-09-10 2010-03-18 Thrubit B.V. Ibuprofen for topical administration

Also Published As

Publication number Publication date
CA2784827A1 (en) 2011-06-23
BR112012014558B1 (pt) 2021-02-02
EP2512446B1 (en) 2015-04-08
WO2011073998A1 (en) 2011-06-23
EP2512446A1 (en) 2012-10-24
JP2013514347A (ja) 2013-04-25
EP2512446A4 (en) 2012-10-24
CN102665681A (zh) 2012-09-12
PL2512446T3 (pl) 2015-08-31
BR112012014558A8 (pt) 2018-04-10
KR101884951B1 (ko) 2018-08-02
DK2512446T3 (en) 2015-06-29
PE20130245A1 (es) 2013-03-08
RU2012129527A (ru) 2014-01-27
MX2012007062A (es) 2012-10-03
BR112012014558B8 (pt) 2021-05-25
KR20120092700A (ko) 2012-08-21
MX352187B (es) 2017-11-13
US20120259018A1 (en) 2012-10-11
AU2010331761A1 (en) 2012-07-12
AU2010331761B2 (en) 2015-09-24
US10085939B2 (en) 2018-10-02
ES2541483T3 (es) 2015-07-21
CA2784827C (en) 2018-10-23
US20150342879A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
BR112012014558A8 (pt) nova composição de hidrogel transdérmico de dexibuprofeno
CY1115980T1 (el) Υδροπηκτες πολυμερων και χρηση αυτων
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
BR112021018159A2 (pt) Método para gerar uma molécula de rna com atividade de silenciamento, célula geneticamente modificada, planta geneticamente modificada, célula vegetal, planta, semente, métodos de produção de uma planta, de tratamento de uma doença e de introdução da atividade de silenciamento
BR112015031913A2 (pt) processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização
AR091454A1 (es) Metodo para preparar una composicion a base de acido hialuronico
BR112018014026A2 (pt) composição líquida compreendendo um polímero múltiplas fases, seu método de preparação e uso
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
BR112013022246A2 (pt) formulações para alisamento capilar a base de queratina, métodos e sistemas
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
EA201600044A1 (ru) Композиции для интродукции рнк в клетки
BRPI1008409B8 (pt) método para produção de cartucho analítico
NO20076536L (no) Bakterielle cellulose-inneholdende formuleringer og fremgangsmate for fremstilling av effektive bakterielle cellulose-inneholdende formuleringer
BR112018014029A2 (pt) composição líquida compreendendo um polímero múltiplas fases e um monômero (met) acrílico, seu método de preparação e uso
UY32010A (es) Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
BR112017016975A2 (pt) processo para produzir aminoácidos a partir de precursores obtidos por fermentação anaeróbica de biomassa fermentável
BR112018012759A2 (pt) polímero de ase, e, composição aquosa contendo tensoativo.
BR112016002342A2 (pt) Microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
BR112014022467A2 (pt) transformantes de rasamsonia
BR112016023624A2 (pt) proteínas de antiporte prótons/ açúcar tonoplásticas e uso do mesmo para o aumento da concentração de sacarose de um órgão de plantas para armazenamento de sacarose
ATE514746T1 (de) Kohlenstoffnanoröhrchen verstärkte polymerzusammensetzung und verfahren zu deren herstellung
CL2009001935A1 (es) Vector que comprende una molécula de ácido nucleico capaz de dirigir la expresión génica en el desarrollo de semillas; célula que lo contiene; método para transformar una célula con dicho vector, y procedimiento para identificar alelos fad3a y fad3b en una planta de lino (div. sol. n°267-06).
BR112018007801A2 (pt) processo para produção de glicóis.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF